Literature DB >> 19555855

Cellular and molecular basis of pulmonary arterial hypertension.

Nicholas W Morrell1, Serge Adnot2, Stephen L Archer3, Jocelyn Dupuis4, Peter Lloyd Jones5, Margaret R MacLean6, Ivan F McMurtry7, Kurt R Stenmark8, Patricia A Thistlethwaite9, Norbert Weissmann10, Jason X-J Yuan11, E Kenneth Weir12.   

Abstract

Pulmonary arterial hypertension (PAH) is caused by functional and structural changes in the pulmonary vasculature, leading to increased pulmonary vascular resistance. The process of pulmonary vascular remodeling is accompanied by endothelial dysfunction, activation of fibroblasts and smooth muscle cells, crosstalk between cells within the vascular wall, and recruitment of circulating progenitor cells. Recent findings have reestablished the role of chronic vasoconstriction in the remodeling process. Although the pathology of PAH in the lung is well known, this article is concerned with the cellular and molecular processes involved. In particular, we focus on the role of the Rho family guanosine triphosphatases in endothelial function and vasoconstriction. The crosstalk between endothelium and vascular smooth muscle is explored in the context of mutations in the bone morphogenetic protein type II receptor, alterations in angiopoietin-1/TIE2 signaling, and the serotonin pathway. We also review the role of voltage-gated K(+) channels and transient receptor potential channels in the regulation of cytosolic [Ca(2+)] and [K(+)], vasoconstriction, proliferation, and cell survival. We highlight the importance of the extracellular matrix as an active regulator of cell behavior and phenotype and evaluate the contribution of the glycoprotein tenascin-c as a key mediator of smooth muscle cell growth and survival. Finally, we discuss the origins of a cell type critical to the process of pulmonary vascular remodeling, the myofibroblast, and review the evidence supporting a contribution for the involvement of endothelial-mesenchymal transition and recruitment of circulating mesenchymal progenitor cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19555855      PMCID: PMC2790324          DOI: 10.1016/j.jacc.2009.04.018

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  127 in total

1.  Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues.

Authors:  A L Wong; Z A Haroon; S Werner; M W Dewhirst; C S Greenberg; K G Peters
Journal:  Circ Res       Date:  1997-10       Impact factor: 17.367

2.  Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction.

Authors:  E K Weir; H L Reeve; J M Huang; E Michelakis; D P Nelson; V Hampl; S L Archer
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

Review 3.  Blood vessel formation: what is its molecular basis?

Authors:  J Folkman; P A D'Amore
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

4.  Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro.

Authors:  M C DeRuiter; R E Poelmann; J C VanMunsteren; V Mironov; R R Markwald; A C Gittenberger-de Groot
Journal:  Circ Res       Date:  1997-04       Impact factor: 17.367

5.  5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats.

Authors:  M R MacLean; G Sweeney; M Baird; K M McCulloch; M Houslay; I Morecroft
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

6.  Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease.

Authors:  P L Jones; K N Cowan; M Rabinovitch
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

7.  Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation.

Authors:  P L Jones; M Rabinovitch
Journal:  Circ Res       Date:  1996-12       Impact factor: 17.367

8.  Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity.

Authors:  Dong Liu; Jian Wang; Bernd Kinzel; Matthias Müeller; Xiaohong Mao; Reginald Valdez; Yongxing Liu; En Li
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

Review 9.  Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease.

Authors:  W H Frishman; S Huberfeld; S Okin; Y H Wang; A Kumar; B Shareef
Journal:  J Clin Pharmacol       Date:  1995-06       Impact factor: 3.126

10.  Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth.

Authors:  P L Jones; J Crack; M Rabinovitch
Journal:  J Cell Biol       Date:  1997-10-06       Impact factor: 10.539

View more
  290 in total

1.  Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension.

Authors:  Anna R Hemnes; Aaron W Trammell; Stephen L Archer; Stuart Rich; Chang Yu; Hui Nian; Niki Penner; Mitchell Funke; Lisa Wheeler; Ivan M Robbins; Eric D Austin; John H Newman; James West
Journal:  Circulation       Date:  2014-10-31       Impact factor: 29.690

Review 2.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 3.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

4.  Assessing response to therapy in idiopathic pulmonary arterial hypertension: a consensus survey of Canadian pulmonary hypertension physicians.

Authors:  Adrienne E Borrie; David N Ostrow; Robert D Levy; John R Swiston
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

Review 5.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

6.  Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension.

Authors:  Meiqian Weng; Michael J Raher; Patricio Leyton; Terry P Combs; Philipp E Scherer; Kenneth D Bloch; Benjamin D Medoff
Journal:  Am J Respir Cell Mol Biol       Date:  2010-11-12       Impact factor: 6.914

Review 7.  Update in Pulmonary Vascular Diseases 2014.

Authors:  Elena A Goncharova; Mark T Gladwin; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

8.  Recapitulation of developing artery muscularization in pulmonary hypertension.

Authors:  Abdul Q Sheikh; Janet K Lighthouse; Daniel M Greif
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

9.  NPY/Y₁ receptor-mediated vasoconstrictory and proliferative effects in pulmonary hypertension.

Authors:  S Crnkovic; B Egemnazarov; P Jain; U Seay; N Gattinger; L M Marsh; Z Bálint; G Kovacs; B Ghanim; W Klepetko; R T Schermuly; N Weissmann; A Olschewski; G Kwapiszewska
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

10.  Hypoxia-induced glucose-6-phosphate dehydrogenase overexpression and -activation in pulmonary artery smooth muscle cells: implication in pulmonary hypertension.

Authors:  Sukrutha Chettimada; Rakhee Gupte; Dhwajbahadur Rawat; Sarah A Gebb; Ivan F McMurtry; Sachin A Gupte
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-12-05       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.